PRMT1-mediated metabolic reprogramming promotes leukemogenesis

This is a Animal Study study (also classified as: In Vitro Study).

Key Points

PRMT1 expression promotes the proliferation of **acute megakaryocytic leukemia** (AMKL) cells, leading to aggressive leukemia progression.
The inhibitor MS023 effectively cures PRMT1-driven leukemia, indicating its potential as a therapeutic option.
Analysis reveals PRMT1 increases glycolysis while downregulating fatty acid oxidation, promoting a metabolic shift in leukemia cells.
Targeting metabolic pathways with agents like 2-deoxy-D-glucose may delay AMKL progression and induce cell differentiation.

Observational analysis shows PRMT1 enhances glycolysis and reduces fatty acid oxidation in AMKL cells, suggesting metabolic targets for therapy.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Su et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share